Thursday, March 15, 2018 9:01:27 AM
Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders
9/29/2017
Dividend is Approximately 83% Payout of Zander's Issued and Outstanding Common Shares
SAN DIEGO, September 29, 2017
Entest BioMedical, Inc. (OTC:ENTB) today announced that its Board of Directors has authorized a distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc. ("Dividend Shares"), a subsidiary of ENTB, to:
?
(a) Holders of record of the outstanding common shares of ENTB as of the record date
(b) Holders of record of the shares of any outstanding series of the preferred shares of ENTB as of the record date.
Entest BioMedical's Chairman & CEO, David Koos stated, "The record date is anticipated to be set as soon as possible after the Form S-1 registering the Dividend Shares under the Securities Act of 1933 is declared effective by the United States Securities and Exchange Commission (SEC). On a pro rata basis, both common and all classes of preferred shareholders will receive this dividend. The Company expects the registration statement to be filed within the next few days with the SEC."
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM